{"disease":{"id":"diffuse-scleroderma","name":"diffuse scleroderma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04464434","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT06425653","title":"Exercise With Scleroderma Functional Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Trakya University","has_results":false},{"nct_id":"NCT03222492","title":"Brentuximab Vedotin for Systemic Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04837131","title":"A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Michael M. Pham","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}